FDB (First Databank) vs Synapse Medicine (2026)
Two medication knowledge companies on opposite sides of the Atlantic, with opposite ideas about where the intelligence belongs. FDB supplies the drug content under most American prescribing systems and licenses it into customers' own systems. Synapse puts machine learning upstream of the clinical decision: it reads and classifies medication information rather than generating recommendations, and it distributes through other software as well as directly into more than a hundred hospitals. The design difference is the useful part. One company owns content that many systems rely on, so a single gap propagates widely. The other deliberately keeps its model out of the recommendation, and its medication software carries Class IIb certification under the EU Medical Device Regulation.
- Its drug knowledge sits underneath most prescribing systems in the United States, so its content is the baseline any additional layer is measured against.
- Content is embedded in customers' own systems, which places hosting and processing questions with the customer.
- Its newer products are framed conservatively, with a prescription agent queuing orders for clinician review.
- The machine learning sits upstream of the clinical decision rather than inside it, reading and classifying medication information rather than generating a recommendation.
- The method and the sources are both named, and distribution runs through other software as well as direct deployment across more than a hundred hospitals.
- Its medication software is certified as a Class IIb medical device under the EU Medical Device Regulation.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. FDB (First Databank) and Synapse Medicine are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | FDB (First Databank) | Synapse Medicine |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Medication Safety & Prescribing |
| Founded | Not recorded | 2017 |
| Headquarters | South San Francisco, California, United States | Bordeaux, France |
| Website | fdbhealth.com | synapse-medicine.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
FDB (First Databank)
-
Product / capability
FDB commercially deployed FDB Script Agent, an AI prescribing tool that converts ambient patient encounter dialogue directly into structured prescriptions.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
FDB, formerly First Databank, supplies the drug knowledge that sits underneath most medication decisions made in the United States. Its databases are integrated into the systems used by most hospitals, physician practices and pharmacies, which means that when a prescribing system warns about an interaction, a dose ceiling or a contraindication, the content behind that warning is frequently this company's rather than the software vendor's.
Source: AI Health Index, September 2026
Synapse Medicine builds what it calls a medication intelligence platform, and the distinctive thing about it is where the machine learning sits. Rather than learning to make a prescribing recommendation, the company uses natural language processing to read and classify medication information from three kinds of unstructured source, manufacturer product documentation, official recommendations from health authorities, and published research, and to assemble that into structured knowledge that drives interaction checking, prescription support and medication reconciliation.
Source: AI Health Index, September 2026
Questions buyers ask
How do FDB (First Databank) and Synapse Medicine handle patient data?
For FDB (First Databank), the licensed databases themselves are delivered inside customers' systems. The agentic products change the exposure: MedProof MCP serves knowledge in patient specific context, so patient details reach FDB on each tailored query, and Script Agent processes spoken clinical conversation.
With Synapse Medicine, patient data processed for care, including age, weight, sex, pregnancy, organ insufficiency, conditions and prescriptions, is kept 20 years from the last consultation in line with the medical council's recommendation; device vigilance data 10 years; research and statistics 3 years; product improvement 12 months. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
Which settings and specialties do FDB (First Databank) and Synapse Medicine cover?
In FDB (First Databank)'s case, the newer products deliberately address both ends of the workflow, with prescription automation aimed at ambulatory practice and order verification aimed at inpatient pharmacy.
For Synapse Medicine, the prescription analysis modules take in the patient characteristics that change prescribing, including age, weight, pregnancy, breastfeeding and organ insufficiency, and include geriatric recommendations. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
What evidence is published for FDB (First Databank) and Synapse Medicine?
With FDB (First Databank), the most notable absence is any comparison of whether agents grounded on FDB content give safer answers than agents that are not.
In Synapse Medicine's case, a research partnership with the national health research institute on detecting drug interactions is on record, and the Bordeaux and Poitiers teaching hospitals are reported by the company to have extended its MedGPT assistant to all their teams after pilots. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The two answer to different regimes and neither position transfers. FDB supplies content into United States systems, where the obligations sit with the software vendors embedding it. Synapse is European and its software is certified as a Class IIb medical device under the MDR. Neither publishes a security attestation, and neither publishes a bias assessment or performance by patient characteristic.
The concentration exposure applies to FDB specifically: when one curated knowledge base underlies most medication decisions in a country, a gap propagates everywhere at once, which is a different question from bias.